Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Haluska

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Theranostics|February 28, 2020
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancerBrittney S Harrington, Yaowu He, Tashbib Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid TumorsAndrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Cancers|April 9, 2020
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian CarcinomaTashbib Khan, Yaowu He, Thomas Kryza, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancerAngela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced CancerAmita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Theranostics|February 28, 2020
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancerBrittney S Harrington, Yaowu He, Tashbib Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid TumorsAndrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Cancers|April 9, 2020
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian CarcinomaTashbib Khan, Yaowu He, Thomas Kryza, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancerAngela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
NAR Cancer|July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceRachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Pageof 7